Protease Inhibitors and Renal Function in Patients with HIV Infection: a Systematic Review.

摘要: Introduction Despite antiretroviral (ARV) therapy reducing renal disease in human immunodeficiency virus overall, there is concern that certain ARVs, particularly tenofovir disoproxil fumarate (TDF) with or without a boosted protease inhibitor (PI), may reduce function over time. It not known whether effects seen PI-based regimens are independent, result from interactions TDF coadministration, artefactual owing to inhibition of tubular creatinine transport by ritonavir cobicistat pharmacoenhancement. The aim this review was conduct systematic studies, weighted toward high-quality evidence, examining changes time regimens.